Shinobu Tamura

Dr. Shinobu Tamura

Emergency and Critical Care Medicine, Wakayama Medical University, Wakayama, Japan
orcid

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2022 in Internal Medicine
Verified
Journal Article
Open access
PDF file
KYKikuaki Yoshida
Kikuaki Yoshida
ASAyaka Sakaki
Ayaka Sakaki
YMYoriko Matsuyama
Yoriko Matsuyama
TMToshiki Mushino
Toshiki Mushino
MMMasanori Matsumoto
Masanori Matsumoto
STShinobu Tamura
Shinobu Tamura
A 57-year-old man without underlying diseases presented with fatigue, loss of appetite, and jaundice 1 week after receiving the first dose of the BNT162b2 mRNA coronavirus disease (COVID-19) vaccine and showed hemolytic anemia with fragmented erythrocytes and severe thrombocytopenia 2 weeks after receiving the vaccine. An ADAMTS13 activity level of <10% and ADAMTS13 inhibitor positivity confirmed the diagnosis of acquired thrombotic thrombocytopenic purpura (TTP). Combination therapy with plasma exchange, corticosteroid, and rituximab improved the clinical outcome. We herein report the first Japanese case of TTP possibly associated with vaccination. Physicians should be alert for this rare but life-threatening hematological complication following COVID-19 vaccination.

4 December 2014 in Case Reports in Infectious Diseases
Verified
Journal Article
Open access
PDF file
YOYuko Ohagi
Yuko Ohagi
STShinobu Tamura
Shinobu Tamura
CNChiaki Nakamoto
Chiaki Nakamoto
HNHiromichi Nakamoto
Hiromichi Nakamoto
MSMasayuki Saijo
Masayuki Saijo
TFTokuzo Fujimoto
Tokuzo Fujimoto
Severe fever with thrombocytopenia syndrome (SFTS) is an emerging infectious and hemorrhagic disease recently described in China and western Japan. A 71-year-old healthy Japanese woman noticed a tick biting her after harvesting in an orchard and removed it herself. She developed diarrhea, anorexia, and chills eight days later. Because these symptoms continued, she visited a primary care physician 6 days after the onset. Laboratory data revealed thrombocytopenia, leukocytopenia, and elevated liver enzymes. She was then referred to our hospital. Although not completely fulfilling the diagnostic criteria used in a retrospective study in Japan, SFTS was suspected, and we detected SFTS virus in the patient’s blood using RT-PCR. However, she recovered without intensive treatment and severe complications 13 days after the onset. In this report, we present a mild clinical course of SFTS virus infection in Japan in detail.

18 September 2025 in Blood
Verified
Journal Article
Closed access
MYMakoto Yoshimitsu
Makoto Yoshimitsu
ICIlseung Choi
Ilseung Choi
SKShigeru Kusumoto
Shigeru Kusumoto
MSMototsugu Shimokawa
Mototsugu Shimokawa
AUAtae Utsunomiya
Atae Utsunomiya
KIKenji Ishitsuka
Kenji Ishitsuka
No standard of care for older patients with aggressive adult T-cell leukemia/lymphoma (ATL) has been established. We evaluated the efficacy of CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisolone) every 2 weeks with mogamulizumab (Moga; Moga-CHOP-14) for older patients with untreated ATL. In this multicenter phase 2 trial, patients aged ≥66 years and those aged 56 to 65 years ineligible for transplantation received 6 cycles of Moga-CHOP-14, followed by 2 cycles of Moga monotherapy. The primary end point was 1-year progression-free survival (PFS). Secondary end points were the complete response (CR) rate, overall response rate (ORR), overall survival (OS), 1-year event-free survival (EFS), and safety. We also investigated the impact of CC chemokine receptor 4 (CCR4) mutation and Moga-associated cutaneous adverse events (cAEs) on PFS and OS. The study protocol was amended to allow the dosing interval to be extended to 21 days at the physician’s discretion. Among 48 evaluable patients, the 1-year PFS was 36.2% (90% confidence interval, 24.9-47.6), with a median follow-up of 1.6 years. The 1-year OS and EFS were 66.0% and 29.9%, respectively. CR and ORR were 64.6% and 91.7%. No unexpected toxicities were observed. Of 47 patients who received ≥2 cycles of CHOP, 20 (42.6%) received CHOP-14, among whom 12 (25.5%) completed 6 cycles. CCR4 mutation and Moga-associated cAEs were associated with better OS. This study showed that Moga-CHOP significantly improved PFS, although the optimal interval for CHOP remains undetermined. Moga-CHOP is now considered a preferable first-line treatment for this patient population. This trial was registered at https://jrct.mhlw.go.jp/en-top as #jRCTs041180130.

Verified
Journal Article
Open access
PDF file
YYYusuke Yamashita
Yusuke Yamashita
SMShuhei Morita
Shuhei Morita
HHHiroki Hosoi
Hiroki Hosoi
HKHiroshi Kobata
Hiroshi Kobata
SKShohei Kishimoto
Shohei Kishimoto
STShinobu Tamura
Shinobu Tamura
Background: Inositol-requiring enzyme 1α (IRE1α), along with protein kinase R-like endoplasmic reticulum kinase (PERK), is a principal regulator of the unfolded protein response (UPR). Recently, the ‘mono’-specific IRE1α inhibitor, kinase-inhibiting RNase attenuator 6 (KIRA6), demonstrated a promising effect against multiple myeloma (MM). Side-stepping the clinical translation, a detailed UPR phenotype in patients with MM and the mechanisms of how KIRA8 works in MM remains unclear. Methods: We characterized UPR phenotypes in the bone marrow of patients with newly diagnosed MM. Then, in human MM cells we analyzed the possible anti-tumor mechanisms of KIRA8 and a Food and Drug Administration (FDA)-approved drug, nilotinib, which we recently identified as having a strong inhibitory effect against IRE1α activity. Finally, we performed an RNA-sequence analysis to detect key IRE1α-related molecules against MM. Results: We illustrated the dominant induction of adaptive UPR markers under IRE1α over the PERK pathway in patients with MM. In human MM cells, KIRA8 decreased cell viability and induced apoptosis, along with the induction of C/EBP homologous protein (CHOP); its combination with bortezomib exhibited more anti-myeloma effects than KIRA8 alone. Nilotinib exerted a similar effect compared with KIRA8. RNA-sequencing identified Polo-like kinase 2 (PLK2) as a KIRA8-suppressed gene. Specifically, the IRE1α overexpression induced PLK2 expression, which was decreased by KIRA8. KIRA8 and PLK2 inhibition exerted anti-myeloma effects with apoptosis induction and the regulation of cell proliferation. Finally, PLK2 was pathologically confirmed to be highly expressed in patients with MM. Conclusion: Dominant activation of adaptive IRE1α was established in patients with MM. Both KIRA8 and nilotinib exhibited anti-myeloma effects, which were enhanced by bortezomib. Adaptive IRE1α signaling and PLK2 could be potential therapeutic targets and biomarkers in MM.

1 January 2014 in Internal Medicine
Verified
Journal Article
Open access
PDF file
MMMasaya Morimoto
Masaya Morimoto
STShinobu Tamura
Shinobu Tamura
THTakahiro Hayakawa
Takahiro Hayakawa
HYHirofumi Yamanishi
Hirofumi Yamanishi
CNChiaki Nakamoto
Chiaki Nakamoto
TFTokuzo Fujimoto
Tokuzo Fujimoto
Phlegmonous gastritis (PG) is a rare, acute, severe infectious disease of the gastric wall that is often fatal due to Streptococcus spp. A 77-year-old man with diabetes and a gastric ulcer was urgently admitted due to prolonged nausea and vomiting. Computed tomography revealed widespread diffuse thickening of the gastric wall, and PG was suspected. The patient expired less than 9 hours after admission despite intensive treatments. Later, an analysis of the blood and gastric juice revealed group A streptococcus (GAS) and virulence factors associated with toxic shock syndrome (TSS). We herein diagnosed a patient with an extremely aggressive course of PG caused by GAS TSS.

31 January 2019 in International Journal of Hematology
Verified
Journal Article
Closed access
PDF file
YYYusuke Yamashita
Yusuke Yamashita
ANAkinori Nishikawa
Akinori Nishikawa
YIYoshifumi Iwahashi
Yoshifumi Iwahashi
MFMasakazu Fujimoto
Masakazu Fujimoto
ISIzumi Sasaki
Izumi Sasaki
STShinobu Tamura
Shinobu Tamura